Type to search

Myeloid Therapeutics and Prime Medicine Enter Into Exclusive Option and Research Collaboration to Develop and Accelerate Next-Generation RNA-based Gene-Editing Technology, RetroT™ | Pharmtech Focus
Prime Therapeutics and Pear Therapeutics Announce First Comprehensive Value-based Agreement for Prescription Digital Therapeutics reSET® and reSET-O® for the Treatment of Substance and Opioid Use Disorders | Pharmtech Focus